Multiple sclerosis

Ozanimod approved for RRMS

Ozanimod (Zeposia) has received TGA approval for use in relapsing remitting MS (RRMS) and has also received a favourable but deferred decision on PBS listing. The drug is a sphingosine 1-phosphate receptor modulator that acts by preventing the movement of lymphocytes into the CNS to cause inflammation and myelin loss. The TGA granted approval of ...

Already a member?

Login to keep reading.

© 2021 the limbic